Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kyowa Hakko Licenses Antibody for Cancer Treatment
March 10, 2008
- Nucleic Acid-Based Drugs Will Be Innovative Drugs of Next Generation: Prof. Morishita
March 10, 2008
- Pfizer Japan Mobilizes All Employees, Officers to Defend Market for Norvasc
March 10, 2008
- GCP for Medical Devices to Be Amended
March 10, 2008
- TOPICS／Dr Karasawa Will Soon Be Back to Office: JMA
March 10, 2008
- Teijin's Gout Treatment TMX-67 Receives Approvable Letter in the EU
March 10, 2008
- Nippon Shinyaku Enters the Field of OB-GYN with IKH-01
March 10, 2008
- Kyowa Hakko Receives Not-Approvable Letter from FDA for Istradefylline
March 10, 2008
- Makers Should Propose Invoice Prices That Reflect Market Prices: Mr Hamada of Toho
March 3, 2008
- Korosho to Survey Measures Taken Overseas to Ensure Safety of Research Using iPS Cells
March 3, 2008
- Iberica Ready to Undertake PI Studies Simultaneously in both Japanese and Americans
March 3, 2008
- Daiichi Sankyo, Eli Lilly Apply for Prasugrel in EU
March 3, 2008
- Number of Privately-Operated Pharmacies to be Halved: Mr Urushibata
March 3, 2008
- New GL on Drugs Obtained from Autologous Cells Announced
March 3, 2008
- BUSINESS NEWS IN BRIEF
March 3, 2008
- STATISTICS／Rate of Death due to Liver Cancer Is Third Highest in Japan
March 3, 2008
- Pharmacies Will Lose or Win Depending on How Many Generics They Dispense
March 3, 2008
- Japan Needs to Introduce Medicoeconomic Assessment of Medical Technologies: Prof Kamae
March 3, 2008
- 50-60% of People Want to Use Generics: Survey
March 3, 2008
- REGULATORY NEWS IN BRIEF
March 3, 2008
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…